Sen-Jam Pharmaceutical Reports Preliminary Phase 2 Results for SJP-002C in COVID-19 Treatment
The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.
Sen-Jam Pharmaceutical has announced preliminary results from its recently completed phase 2 clinical trial evaluating SJP-002C, a novel therapeutic for upper respiratory infections, including COVID-19.
According to the company, SJP-002C demonstrated a strong safety profile, with no adverse events reported during the trial period. The investigational agent also showed efficacy in reducing symptoms during the early stages of treatment, particularly on days 1 and 2.
"The strong safety profile and early symptom improvements are promising indicators of SJP-002C's potential to make a meaningful impact in COVID-19 care," Jackie Iversen, RPh, MS, Chief Clinical Officer and Co-Founder of Sen-Jam Pharmaceutical, said in a press release.1
In a June 2024 press release announcing the full 150-participant enrollment in the clinical trial, Sen-Jam Pharmaceutical described SJP-002C as a multitargeted anti-inflammatory with antiviral capabilities that are effective against various viral strains. The medication could potentially be suitable for a broad population needing treatment to reduce symptoms and prevent respiratory infections from advancing to pneumonia and cytokine storm, the company said.2
At that time, Shen-Jam also reported that a partner company, KVK-Tech, was scheduled to submit FDA manufacturing batches by the fourth quarter of 2024. "Our goal is to offer this treatment at a significantly lower cost than existing options such as Paxlovid, making it accessible to a larger patient population without creating a multitude of drug-drug interactions," the company said in the release.2
The company is currently reviewing additional clinical data and considering further studies to explore SJP-002C’s broader applications. While further research is needed to confirm statistical and clinical significance, these preliminary findings support continued investigation into the medication's potential role in upper respiratory infection treatment.1
